APO Research
Talk to an analyst

APO RESEARCH · REPORT

Live and Attenuated Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Live and Attenuated Vaccine Market Analysis and Forecast 2026-2032

21 December 2025195 pages

Choose your research edition.

Industry ResearchLive and Attenuated Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Live and Attenuated Vaccine Industry Growth and Trends Forecast to 2032105 pages · $3,450 USDMarket StructureGlobal Live and Attenuated Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Live and Attenuated Vaccine Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Live and Attenuated Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Live and Attenuated Vaccine market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Live and Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Live and Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Live and Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Live and Attenuated Vaccine is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global manufacturers of Live and Attenuated Vaccine include Sanofi, Johnson & Johnson, Merck & Co., Pfizer, Inc, GlaxoSmithKline, Serum Institute, MedImmune, LLC, Emergent BioSolutions, Inc. and CSL Limited, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Live and Attenuated Vaccine, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Live and Attenuated Vaccine, also provides the sales of main regions and countries. Of the upcoming market potential for Live and Attenuated Vaccine, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Live and Attenuated Vaccine sales, revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Live and Attenuated Vaccine market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2021 to 2032. Evaluation and forecast the market size for Live and Attenuated Vaccine sales, projected growth trends, production technology, application and end-user industry.

Live and Attenuated Vaccine Segment by Company

Sanofi

Johnson & Johnson

Merck & Co.

Pfizer, Inc

GlaxoSmithKline

Serum Institute

MedImmune, LLC

Emergent BioSolutions, Inc.

CSL Limited

Astellas Pharma Inc

Live and Attenuated Vaccine Segment by Type

Pediatric Vaccine

Adult Vaccines

Live and Attenuated Vaccine Segment by Application

Clinics

Diagnostic Centers

Hospitals

Research Institute

Others

Live and Attenuated Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Live and Attenuated Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Live and Attenuated Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Live and Attenuated Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type and by application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Sales (consumption), revenue of Live and Attenuated Vaccine in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.

Chapter 4: Detailed analysis of Live and Attenuated Vaccine manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Live and Attenuated Vaccine sales, revenue, price, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, sales, and revenue for each segment.

Chapter 9: Europe by type, by application and by country, sales, and revenue for each segment.

Chapter 10: China type, by application, sales, and revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, sales, and revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, sales, and revenue for each segment.

Chapter 13: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.

Chapter 14: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Live and Attenuated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Pediatric Vaccine Major Manufacturers Table 3. Adult Vaccines Major Manufacturers Table 4. Global Live and Attenuated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Clinics Major Manufacturers Table 6. Diagnostic Centers Major Manufacturers Table 7. Hospitals Major Manufacturers Table 8. Research Institute Major Manufacturers Table 9. Others Major Manufacturers Table 10. Live and Attenuated Vaccine Industry Trends Table 11. Live and Attenuated Vaccine Industry Drivers Table 12. Live and Attenuated Vaccine Industry Opportunities and Challenges Table 13. Live and Attenuated Vaccine Industry Restraints Table 14. Global Live and Attenuated Vaccine Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 15. Global Live and Attenuated Vaccine Revenue by Region (2021-2026) & (US$ Million) Table 16. Global Live and Attenuated Vaccine Revenue by Region (2027-2032) & (US$ Million) Table 17. Global Live and Attenuated Vaccine Revenue Market Share by Region (2021-2026) Table 18. Global Live and Attenuated Vaccine Revenue Market Share by Region (2027-2032) Table 19. Global Live and Attenuated Vaccine Sales Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (k units) Table 20. Global Live and Attenuated Vaccine Sales by Region (2021-2026) & (k units) Table 21. Global Live and Attenuated Vaccine Sales by Region (2027-2032) & (k units) Table 22. Global Live and Attenuated Vaccine Sales Market Share by Region (2021-2026) Table 23. Global Live and Attenuated Vaccine Sales Market Share by Region (2027-2032) Table 24. Global Live and Attenuated Vaccine Revenue by Manufacturers (US$ Million) & (2021-2026) Table 25. Global Live and Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026) Table 26. Global Live and Attenuated Vaccine Sales by Manufacturers (US$ Million) & (2021-2026) Table 27. Global Live and Attenuated Vaccine Sales Market Share by Manufacturers (2021-2026) Table 28. Global Live and Attenuated Vaccine Sales Price (US$/unit) of Manufacturers (2021-2026) Table 29. Global Live and Attenuated Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 30. Global Live and Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters Table 31. Global Live and Attenuated Vaccine Manufacturers, Product Type & Application Table 32. Global Live and Attenuated Vaccine Manufacturers' Establishment Date Table 33. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 34. Global Live and Attenuated Vaccine by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 35. Global Live and Attenuated Vaccine Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 37. Global Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 38. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2026) Table 39. Global Live and Attenuated Vaccine Revenue Market Share by Type (2027-2032) Table 40. Global Live and Attenuated Vaccine Sales by Type 2021 VS 2025 VS 2032 (k units) Table 41. Global Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 42. Global Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 43. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2026) Table 44. Global Live and Attenuated Vaccine Sales Market Share by Type (2027-2032) Table 45. Global Live and Attenuated Vaccine Price by Type (2021-2026) & (US$/unit) Table 46. Global Live and Attenuated Vaccine Price by Type (2027-2032) & (US$/unit) Table 47. Global Live and Attenuated Vaccine Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 49. Global Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 50. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2026) Table 51. Global Live and Attenuated Vaccine Revenue Market Share by Application (2027-2032) Table 52. Global Live and Attenuated Vaccine Sales by Application 2021 VS 2025 VS 2032 (k units) Table 53. Global Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 54. Global Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 55. Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2026) Table 56. Global Live and Attenuated Vaccine Sales Market Share by Application (2027-2032) Table 57. Global Live and Attenuated Vaccine Price by Application (2021-2026) & (US$/unit) Table 58. Global Live and Attenuated Vaccine Price by Application (2027-2032) & (US$/unit) Table 59. Sanofi Company Information Table 60. Sanofi Business Overview Table 61. Sanofi Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 62. Sanofi Live and Attenuated Vaccine Product Portfolio Table 63. Sanofi Recent Development Table 64. Johnson & Johnson Company Information Table 65. Johnson & Johnson Business Overview Table 66. Johnson & Johnson Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 67. Johnson & Johnson Live and Attenuated Vaccine Product Portfolio Table 68. Johnson & Johnson Recent Development Table 69. Merck & Co. Company Information Table 70. Merck & Co. Business Overview Table 71. Merck & Co. Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 72. Merck & Co. Live and Attenuated Vaccine Product Portfolio Table 73. Merck & Co. Recent Development Table 74. Pfizer, Inc Company Information Table 75. Pfizer, Inc Business Overview Table 76. Pfizer, Inc Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 77. Pfizer, Inc Live and Attenuated Vaccine Product Portfolio Table 78. Pfizer, Inc Recent Development Table 79. GlaxoSmithKline Company Information Table 80. GlaxoSmithKline Business Overview Table 81. GlaxoSmithKline Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 82. GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio Table 83. GlaxoSmithKline Recent Development Table 84. Serum Institute Company Information Table 85. Serum Institute Business Overview Table 86. Serum Institute Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. Serum Institute Live and Attenuated Vaccine Product Portfolio Table 88. Serum Institute Recent Development Table 89. MedImmune, LLC Company Information Table 90. MedImmune, LLC Business Overview Table 91. MedImmune, LLC Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. MedImmune, LLC Live and Attenuated Vaccine Product Portfolio Table 93. MedImmune, LLC Recent Development Table 94. Emergent BioSolutions, Inc. Company Information Table 95. Emergent BioSolutions, Inc. Business Overview Table 96. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio Table 98. Emergent BioSolutions, Inc. Recent Development Table 99. CSL Limited Company Information Table 100. CSL Limited Business Overview Table 101. CSL Limited Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. CSL Limited Live and Attenuated Vaccine Product Portfolio Table 103. CSL Limited Recent Development Table 104. Astellas Pharma Inc Company Information Table 105. Astellas Pharma Inc Business Overview Table 106. Astellas Pharma Inc Live and Attenuated Vaccine Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio Table 108. Astellas Pharma Inc Recent Development Table 109. North America Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 110. North America Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 111. North America Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 112. North America Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 113. North America Live and Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 114. North America Live and Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 115. North America Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 116. North America Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 117. North America Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 118. North America Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 119. North America Live and Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 120. North America Live and Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 121. North America Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 122. North America Live and Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 123. North America Live and Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 124. North America Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 125. North America Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 126. North America Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 127. North America Live and Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 128. North America Live and Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 129. United States Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 130. Canada Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 131. Mexico Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 132. Europe Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 133. Europe Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 134. Europe Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 135. Europe Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 136. Europe Live and Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 137. Europe Live and Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 138. Europe Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 139. Europe Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 140. Europe Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 141. Europe Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 142. Europe Live and Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 143. Europe Live and Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 144. Europe Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 145. Europe Live and Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 146. Europe Live and Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 147. Europe Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 148. Europe Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 149. Europe Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 150. Europe Live and Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 151. Europe Live and Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 152. Germany Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 153. France Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 154. U.K. Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 155. Italy Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 156. Russia Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 157. Spain Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 158. Netherlands Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 159. Switzerland Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 160. Sweden Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 161. Poland Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 162. China Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 163. China Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 164. China Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 165. China Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 166. China Live and Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 167. China Live and Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 168. China Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 169. China Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 170. China Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 171. China Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 172. China Live and Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 173. China Live and Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 174. Asia Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 175. Asia Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 176. Asia Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 177. Asia Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 178. Asia Live and Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 179. Asia Live and Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 180. Asia Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 181. Asia Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 182. Asia Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 183. Asia Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 184. Asia Live and Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 185. Asia Live and Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 186. Asia Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 187. Asia Live and Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 188. Asia Live and Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 189. Asia Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 190. Asia Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 191. Asia Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 192. Asia Live and Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 193. Asia Live and Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 194. Japan Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 195. South Korea Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 196. India Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 197. Australia Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 198. Taiwan Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 199. Southeast Asia Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 200. SAMEA Live and Attenuated Vaccine Revenue by Type (2021-2026) & (US$ Million) Table 201. SAMEA Live and Attenuated Vaccine Revenue by Type (2027-2032) & (US$ Million) Table 202. SAMEA Live and Attenuated Vaccine Sales by Type (2021-2026) & (k units) Table 203. SAMEA Live and Attenuated Vaccine Sales by Type (2027-2032) & (k units) Table 204. SAMEA Live and Attenuated Vaccine Sales Price by Type (2021-2026) & (US$/unit) Table 205. SAMEA Live and Attenuated Vaccine Sales Price by Type (2027-2032) & (US$/unit) Table 206. SAMEA Live and Attenuated Vaccine Revenue by Application (2021-2026) & (US$ Million) Table 207. SAMEA Live and Attenuated Vaccine Revenue by Application (2027-2032) & (US$ Million) Table 208. SAMEA Live and Attenuated Vaccine Sales by Application (2021-2026) & (k units) Table 209. SAMEA Live and Attenuated Vaccine Sales by Application (2027-2032) & (k units) Table 210. SAMEA Live and Attenuated Vaccine Sales Price by Application (2021-2026) & (US$/unit) Table 211. SAMEA Live and Attenuated Vaccine Sales Price by Application (2027-2032) & (US$/unit) Table 212. SAMEA Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 213. SAMEA Live and Attenuated Vaccine Revenue Grow Rate by Country (2021-2026) & (US$ Million) Table 214. SAMEA Live and Attenuated Vaccine Revenue Grow Rate by Country (2027-2032) & (US$ Million) Table 215. SAMEA Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032) & (k units) Table 216. SAMEA Live and Attenuated Vaccine Sales by Country (2021-2026) & (k units) Table 217. SAMEA Live and Attenuated Vaccine Sales by Country (2027-2032) & (k units) Table 218. SAMEA Live and Attenuated Vaccine Sales Price by Country (2021-2026) & (US$/unit) Table 219. SAMEA Live and Attenuated Vaccine Sales Price by Country (2027-2032) & (US$/unit) Table 220. Brazil Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 221. Argentina Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 222. Chile Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 223. Colombia Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 224. Peru Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 225. Saudi Arabia Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 226. Israel Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 227. UAE Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 228. Turkey Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 229. Iran Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 230. Egypt Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Table 231. Key Raw Materials Table 232. Raw Materials Key Suppliers Table 233. Live and Attenuated Vaccine Distributors List Table 234. Live and Attenuated Vaccine Customers List Table 235. Research Programs/Design for This Report Table 236. Authors List of This Report Table 237. Secondary Sources Table 238. Primary Sources List of Figures Figure 1. Live and Attenuated Vaccine Image Figure 2. Global Live and Attenuated Vaccine Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Live and Attenuated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 4. Pediatric Vaccine Image Figure 5. Adult Vaccines Image Figure 6. Global Live and Attenuated Vaccine Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Live and Attenuated Vaccine Market Size Share 2021 VS 2025 VS 2032 Figure 8. Clinics Image Figure 9. Diagnostic Centers Image Figure 10. Hospitals Image Figure 11. Research Institute Image Figure 12. Others Image Figure 13. Global Live and Attenuated Vaccine Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 14. Global Live and Attenuated Vaccine Revenue (2021-2032) & (US$ Million) Figure 15. Global Live and Attenuated Vaccine Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 16. Global Live and Attenuated Vaccine Revenue Market Share by Region: 2025 Versus 2032 Figure 17. Global Live and Attenuated Vaccine Revenue Market Share by Region (2021-2032) Figure 18. Global Live and Attenuated Vaccine Sales (2021-2032) & (k units) Figure 19. Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 20. Global Live and Attenuated Vaccine Sales Market Share by Region (2021-2032) Figure 21. US & Canada & Mexico Live and Attenuated Vaccine Sales YoY (2021-2032) & (k units) Figure 22. Europe Live and Attenuated Vaccine Sales YoY (2021-2032) & (k units) Figure 23. China Live and Attenuated Vaccine Sales YoY (2021-2032) & (k units) Figure 24. Asia (Excluding China) Live and Attenuated Vaccine Sales YoY (2021-2032) & (k units) Figure 25. South America, Middle East and Africa Live and Attenuated Vaccine Sales YoY (2021-2032) & (k units) Figure 26. Global Live and Attenuated Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025 Figure 27. Global Live and Attenuated Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025 Figure 28. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 29. Global Live and Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 30. Global Live and Attenuated Vaccine Revenue Market Share by Type 2021 VS 2025 VS 2032 Figure 31. Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2032) Figure 32. Global Live and Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032) & (k units) Figure 33. Global Live and Attenuated Vaccine Sales Market Share by Type 2021 VS 2025 VS 2032 Figure 34. Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2032) Figure 35. Global Live and Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 36. Global Live and Attenuated Vaccine Revenue Market Share by Application 2021 VS 2025 VS 2032 Figure 37. Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2032) Figure 38. Global Live and Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032) & (k units) Figure 39. Global Live and Attenuated Vaccine Sales Market Share by Application 2021 VS 2025 VS 2032 Figure 40. Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2032) Figure 41. North America Live and Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 42. North America Live and Attenuated Vaccine Sales Share by Type (2021-2032) Figure 43. North America Live and Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 44. North America Live and Attenuated Vaccine Sales Share by Application (2021-2032) Figure 45. North America Live and Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 46. North America Live and Attenuated Vaccine Sales Share by Country (2021-2032) Figure 47. Europe Live and Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 48. Europe Live and Attenuated Vaccine Sales Share by Type (2021-2032) Figure 49. Europe Live and Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 50. Europe Live and Attenuated Vaccine Sales Share by Application (2021-2032) Figure 51. Europe Live and Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 52. Europe Live and Attenuated Vaccine Sales Share by Country (2021-2032) Figure 53. China Live and Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 54. China Live and Attenuated Vaccine Sales Share by Type (2021-2032) Figure 55. China Live and Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 56. China Live and Attenuated Vaccine Sales Share by Application (2021-2032) Figure 57. Asia Live and Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 58. Asia Live and Attenuated Vaccine Sales Share by Type (2021-2032) Figure 59. Asia Live and Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 60. Asia Live and Attenuated Vaccine Sales Share by Application (2021-2032) Figure 61. Asia Live and Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 62. Asia Live and Attenuated Vaccine Sales Share by Country (2021-2032) Figure 63. SAMEA Live and Attenuated Vaccine Revenue Share by Type (2021-2032) Figure 64. SAMEA Live and Attenuated Vaccine Sales Share by Type (2021-2032) Figure 65. SAMEA Live and Attenuated Vaccine Revenue Share by Application (2021-2032) Figure 66. SAMEA Live and Attenuated Vaccine Sales Share by Application (2021-2032) Figure 67. SAMEA Live and Attenuated Vaccine Revenue Share by Country (2021-2032) Figure 68. SAMEA Live and Attenuated Vaccine Sales Share by Country (2021-2032) Figure 69. Live and Attenuated Vaccine Value Chain Figure 70. Manufacturing Cost Structure Figure 71. Live and Attenuated Vaccine Production Mode & Process Figure 72. Direct Comparison with Distribution Share Figure 73. Distributors Profiles Figure 74. Years Considered Figure 75. Research Process Figure 76. Key Executives Interviewed

Scope & coverage.

Types
  • Pediatric Vaccine
  • Adult Vaccines
Applications
  • Clinics
  • Diagnostic Centers
  • Hospitals
  • Research Institute
  • Others
Companies covered
  • Sanofi
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer, Inc
  • GlaxoSmithKline
  • Serum Institute
  • MedImmune, LLC
  • Emergent BioSolutions, Inc.
  • CSL Limited
  • Astellas Pharma Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Live and Attenuated Vaccine Market by Type
  3. 1.2.1 Global Live and Attenuated Vaccine Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Pediatric Vaccine
  5. 1.2.3 Adult Vaccines
  6. 1.3 Live and Attenuated Vaccine Market by Application
  7. 1.3.1 Global Live and Attenuated Vaccine Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Clinics
  9. 1.3.3 Diagnostic Centers
  10. 1.3.4 Hospitals
  11. 1.3.5 Research Institute
  12. 1.3.6 Others
  13. 1.4 Assumptions and Limitations
  14. 1.5 Study Goals and Objectives
2 Live and Attenuated Vaccine Market Dynamics
  1. 2.1 Live and Attenuated Vaccine Industry Trends
  2. 2.2 Live and Attenuated Vaccine Industry Drivers
  3. 2.3 Live and Attenuated Vaccine Industry Opportunities and Challenges
  4. 2.4 Live and Attenuated Vaccine Industry Restraints
3 Global Market Growth Prospects
  1. 3.1 Global Live and Attenuated Vaccine Revenue Estimates and Forecasts (2021-2032)
  2. 3.2 Global Live and Attenuated Vaccine Revenue by Region
  3. 3.2.1 Global Live and Attenuated Vaccine Revenue by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Live and Attenuated Vaccine Revenue by Region (2021-2026)
  5. 3.2.3 Global Live and Attenuated Vaccine Revenue by Region (2027-2032)
  6. 3.2.4 Global Live and Attenuated Vaccine Revenue Market Share by Region (2021-2032)
  7. 3.3 Global Live and Attenuated Vaccine Sales Estimates and Forecasts 2021-2032
  8. 3.4 Global Live and Attenuated Vaccine Sales by Region
  9. 3.4.1 Global Live and Attenuated Vaccine Sales by Region: 2021 VS 2025 VS 2032
  10. 3.4.2 Global Live and Attenuated Vaccine Sales by Region (2021-2026)
  11. 3.4.3 Global Live and Attenuated Vaccine Sales by Region (2027-2032)
  12. 3.4.4 Global Live and Attenuated Vaccine Sales Market Share by Region (2021-2032)
  13. 3.5 US & Canada & Mexico
  14. 3.6 Europe
  15. 3.7 China
  16. 3.8 Asia (Excluding China)
  17. 3.9 South America, Middle East and Africa
4 Market Competitive Landscape by Manufacturers
  1. 4.1 Global Live and Attenuated Vaccine Revenue by Manufacturers
  2. 4.1.1 Global Live and Attenuated Vaccine Revenue by Manufacturers (2021-2026)
  3. 4.1.2 Global Live and Attenuated Vaccine Revenue Market Share by Manufacturers (2021-2026)
  4. 4.1.3 Global Live and Attenuated Vaccine Manufacturers Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Live and Attenuated Vaccine Sales by Manufacturers
  6. 4.2.1 Global Live and Attenuated Vaccine Sales by Manufacturers (2021-2026)
  7. 4.2.2 Global Live and Attenuated Vaccine Sales Market Share by Manufacturers (2021-2026)
  8. 4.2.3 Global Live and Attenuated Vaccine Manufacturers Sales Share Top 10 and Top 5 in 2025
  9. 4.3 Global Live and Attenuated Vaccine Sales Price by Manufacturers (2021-2026)
  10. 4.4 Global Live and Attenuated Vaccine Key Manufacturers Ranking, 2024 VS 2025 VS 2026
  11. 4.5 Global Live and Attenuated Vaccine Key Manufacturers Manufacturing Sites & Headquarters
  12. 4.6 Global Live and Attenuated Vaccine Manufacturers, Product Type & Application
  13. 4.7 Global Live and Attenuated Vaccine Manufacturers' Establishment Date
  14. 4.8 Market Competitive Analysis
  15. 4.8.1 Global Live and Attenuated Vaccine Market CR5 and HHI
  16. 4.8.2 2025 Live and Attenuated Vaccine Tier 1, Tier 2, and Tier 3
5 Live and Attenuated Vaccine Market by Type
  1. 5.1 Global Live and Attenuated Vaccine Revenue by Type
  2. 5.1.1 Global Live and Attenuated Vaccine Revenue by Type (2021 VS 2025 VS 2032)
  3. 5.1.2 Global Live and Attenuated Vaccine Revenue by Type (2021-2032) & (US$ Million)
  4. 5.1.3 Global Live and Attenuated Vaccine Revenue Market Share by Type (2021-2032)
  5. 5.2 Global Live and Attenuated Vaccine Sales by Type
  6. 5.2.1 Global Live and Attenuated Vaccine Sales by Type (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Live and Attenuated Vaccine Sales by Type (2021-2032) & (k units)
  8. 5.2.3 Global Live and Attenuated Vaccine Sales Market Share by Type (2021-2032)
  9. 5.3 Global Live and Attenuated Vaccine Price by Type
6 Live and Attenuated Vaccine Market by Application
  1. 6.1 Global Live and Attenuated Vaccine Revenue by Application
  2. 6.1.1 Global Live and Attenuated Vaccine Revenue by Application (2021 VS 2025 VS 2032)
  3. 6.1.2 Global Live and Attenuated Vaccine Revenue by Application (2021-2032) & (US$ Million)
  4. 6.1.3 Global Live and Attenuated Vaccine Revenue Market Share by Application (2021-2032)
  5. 6.2 Global Live and Attenuated Vaccine Sales by Application
  6. 6.2.1 Global Live and Attenuated Vaccine Sales by Application (2021 VS 2025 VS 2032)
  7. 6.2.2 Global Live and Attenuated Vaccine Sales by Application (2021-2032) & (k units)
  8. 6.2.3 Global Live and Attenuated Vaccine Sales Market Share by Application (2021-2032)
  9. 6.3 Global Live and Attenuated Vaccine Price by Application
7 Company Profiles
  1. 7.1 Sanofi
  2. 7.1.1 Sanofi Company Information
  3. 7.1.2 Sanofi Business Overview
  4. 7.1.3 Sanofi Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  5. 7.1.4 Sanofi Live and Attenuated Vaccine Product Portfolio
  6. 7.1.5 Sanofi Recent Developments
  7. 7.2 Johnson & Johnson
  8. 7.2.1 Johnson & Johnson Company Information
  9. 7.2.2 Johnson & Johnson Business Overview
  10. 7.2.3 Johnson & Johnson Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  11. 7.2.4 Johnson & Johnson Live and Attenuated Vaccine Product Portfolio
  12. 7.2.5 Johnson & Johnson Recent Developments
  13. 7.3 Merck & Co.
  14. 7.3.1 Merck & Co. Company Information
  15. 7.3.2 Merck & Co. Business Overview
  16. 7.3.3 Merck & Co. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  17. 7.3.4 Merck & Co. Live and Attenuated Vaccine Product Portfolio
  18. 7.3.5 Merck & Co. Recent Developments
  19. 7.4 Pfizer, Inc
  20. 7.4.1 Pfizer, Inc Company Information
  21. 7.4.2 Pfizer, Inc Business Overview
  22. 7.4.3 Pfizer, Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer, Inc Live and Attenuated Vaccine Product Portfolio
  24. 7.4.5 Pfizer, Inc Recent Developments
  25. 7.5 GlaxoSmithKline
  26. 7.5.1 GlaxoSmithKline Company Information
  27. 7.5.2 GlaxoSmithKline Business Overview
  28. 7.5.3 GlaxoSmithKline Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline Live and Attenuated Vaccine Product Portfolio
  30. 7.5.5 GlaxoSmithKline Recent Developments
  31. 7.6 Serum Institute
  32. 7.6.1 Serum Institute Company Information
  33. 7.6.2 Serum Institute Business Overview
  34. 7.6.3 Serum Institute Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  35. 7.6.4 Serum Institute Live and Attenuated Vaccine Product Portfolio
  36. 7.6.5 Serum Institute Recent Developments
  37. 7.7 MedImmune, LLC
  38. 7.7.1 MedImmune, LLC Company Information
  39. 7.7.2 MedImmune, LLC Business Overview
  40. 7.7.3 MedImmune, LLC Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  41. 7.7.4 MedImmune, LLC Live and Attenuated Vaccine Product Portfolio
  42. 7.7.5 MedImmune, LLC Recent Developments
  43. 7.8 Emergent BioSolutions, Inc.
  44. 7.8.1 Emergent BioSolutions, Inc. Company Information
  45. 7.8.2 Emergent BioSolutions, Inc. Business Overview
  46. 7.8.3 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  47. 7.8.4 Emergent BioSolutions, Inc. Live and Attenuated Vaccine Product Portfolio
  48. 7.8.5 Emergent BioSolutions, Inc. Recent Developments
  49. 7.9 CSL Limited
  50. 7.9.1 CSL Limited Company Information
  51. 7.9.2 CSL Limited Business Overview
  52. 7.9.3 CSL Limited Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  53. 7.9.4 CSL Limited Live and Attenuated Vaccine Product Portfolio
  54. 7.9.5 CSL Limited Recent Developments
  55. 7.10 Astellas Pharma Inc
  56. 7.10.1 Astellas Pharma Inc Company Information
  57. 7.10.2 Astellas Pharma Inc Business Overview
  58. 7.10.3 Astellas Pharma Inc Live and Attenuated Vaccine Sales, Revenue, Price and Gross Margin (2021-2026)
  59. 7.10.4 Astellas Pharma Inc Live and Attenuated Vaccine Product Portfolio
  60. 7.10.5 Astellas Pharma Inc Recent Developments
8 North America
  1. 8.1 North America Live and Attenuated Vaccine Market Size by Type
  2. 8.1.1 North America Live and Attenuated Vaccine Revenue by Type (2021-2032)
  3. 8.1.2 North America Live and Attenuated Vaccine Sales by Type (2021-2032)
  4. 8.1.3 North America Live and Attenuated Vaccine Price by Type (2021-2032)
  5. 8.2 North America Live and Attenuated Vaccine Market Size by Application
  6. 8.2.1 North America Live and Attenuated Vaccine Revenue by Application (2021-2032)
  7. 8.2.2 North America Live and Attenuated Vaccine Sales by Application (2021-2032)
  8. 8.2.3 North America Live and Attenuated Vaccine Price by Application (2021-2032)
  9. 8.3 North America Live and Attenuated Vaccine Market Size by Country
  10. 8.3.1 North America Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 8.3.2 North America Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 8.3.3 North America Live and Attenuated Vaccine Price by Country (2021-2032)
  13. 8.3.4 United States
  14. 8.3.5 Canada
  15. 8.3.6 Mexico
9 Europe
  1. 9.1 Europe Live and Attenuated Vaccine Market Size by Type
  2. 9.1.1 Europe Live and Attenuated Vaccine Revenue by Type (2021-2032)
  3. 9.1.2 Europe Live and Attenuated Vaccine Sales by Type (2021-2032)
  4. 9.1.3 Europe Live and Attenuated Vaccine Price by Type (2021-2032)
  5. 9.2 Europe Live and Attenuated Vaccine Market Size by Application
  6. 9.2.1 Europe Live and Attenuated Vaccine Revenue by Application (2021-2032)
  7. 9.2.2 Europe Live and Attenuated Vaccine Sales by Application (2021-2032)
  8. 9.2.3 Europe Live and Attenuated Vaccine Price by Application (2021-2032)
  9. 9.3 Europe Live and Attenuated Vaccine Market Size by Country
  10. 9.3.1 Europe Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 9.3.2 Europe Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 9.3.3 Europe Live and Attenuated Vaccine Price by Country (2021-2032)
  13. 9.3.4 Germany
  14. 9.3.5 France
  15. 9.3.6 U.K.
  16. 9.3.7 Italy
  17. 9.3.8 Russia
  18. 9.3.9 Spain
  19. 9.3.10 Netherlands
10 China
  1. 10.1 China Live and Attenuated Vaccine Market Size by Type
  2. 10.1.1 China Live and Attenuated Vaccine Revenue by Type (2021-2032)
  3. 10.1.2 China Live and Attenuated Vaccine Sales by Type (2021-2032)
  4. 10.1.3 China Live and Attenuated Vaccine Price by Type (2021-2032)
  5. 10.2 China Live and Attenuated Vaccine Market Size by Application
  6. 10.2.1 China Live and Attenuated Vaccine Revenue by Application (2021-2032)
  7. 10.2.2 China Live and Attenuated Vaccine Sales by Application (2021-2032)
  8. 10.2.3 China Live and Attenuated Vaccine Price by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Live and Attenuated Vaccine Market Size by Type
  2. 11.1.1 Asia Live and Attenuated Vaccine Revenue by Type (2021-2032)
  3. 11.1.2 Asia Live and Attenuated Vaccine Sales by Type (2021-2032)
  4. 11.1.3 Asia Live and Attenuated Vaccine Price by Type (2021-2032)
  5. 11.2 Asia Live and Attenuated Vaccine Market Size by Application
  6. 11.2.1 Asia Live and Attenuated Vaccine Revenue by Application (2021-2032)
  7. 11.2.2 Asia Live and Attenuated Vaccine Sales by Application (2021-2032)
  8. 11.2.3 Asia Live and Attenuated Vaccine Price by Application (2021-2032)
  9. 11.3 Asia Live and Attenuated Vaccine Market Size by Country
  10. 11.3.1 Asia Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 11.3.2 Asia Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 11.3.3 Asia Live and Attenuated Vaccine Price by Country (2021-2032)
  13. 11.3.4 Japan
  14. 11.3.5 South Korea
  15. 11.3.6 India
  16. 11.3.7 Australia
  17. 11.3.8 Taiwan
  18. 11.3.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Live and Attenuated Vaccine Market Size by Type
  2. 12.1.1 SAMEA Live and Attenuated Vaccine Revenue by Type (2021-2032)
  3. 12.1.2 SAMEA Live and Attenuated Vaccine Sales by Type (2021-2032)
  4. 12.1.3 SAMEA Live and Attenuated Vaccine Price by Type (2021-2032)
  5. 12.2 SAMEA Live and Attenuated Vaccine Market Size by Application
  6. 12.2.1 SAMEA Live and Attenuated Vaccine Revenue by Application (2021-2032)
  7. 12.2.2 SAMEA Live and Attenuated Vaccine Sales by Application (2021-2032)
  8. 12.2.3 SAMEA Live and Attenuated Vaccine Price by Application (2021-2032)
  9. 12.3 SAMEA Live and Attenuated Vaccine Market Size by Country
  10. 12.3.1 SAMEA Live and Attenuated Vaccine Revenue Grow Rate by Country (2021 VS 2025 VS 2032)
  11. 12.3.2 SAMEA Live and Attenuated Vaccine Sales by Country (2021 VS 2025 VS 2032)
  12. 12.3.3 SAMEA Live and Attenuated Vaccine Price by Country (2021-2032)
  13. 12.3.4 Brazil
  14. 12.3.5 Argentina
  15. 12.3.6 Chile
  16. 12.3.7 Colombia
  17. 12.3.8 Peru
  18. 12.3.9 Saudi Arabia
  19. 12.3.10 Israel
  20. 12.3.11 UAE
  21. 12.3.12 Turkey
  22. 12.3.13 Iran
  23. 12.3.14 Egypt
13 Value Chain and Sales Channels Analysis
  1. 13.1 Live and Attenuated Vaccine Value Chain Analysis
  2. 13.1.1 Live and Attenuated Vaccine Key Raw Materials
  3. 13.1.2 Raw Materials Key Suppliers
  4. 13.1.3 Manufacturing Cost Structure
  5. 13.1.4 Live and Attenuated Vaccine Production Mode & Process
  6. 13.2 Live and Attenuated Vaccine Sales Channels Analysis
  7. 13.2.1 Direct Comparison with Distribution Share
  8. 13.2.2 Live and Attenuated Vaccine Distributors
  9. 13.2.3 Live and Attenuated Vaccine Customers
14 Concluding Insights
    15 Appendix
    1. 15.1 Reasons for Doing This Study
    2. 15.2 Research Methodology
    3. 15.3 Research Process
    4. 15.4 Authors List of This Report
    5. 15.5 Data Source
    6. 15.5.1 Secondary Sources
    7. 15.5.2 Primary Sources
    8. 15.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst